Member Info for LordSnooty

take up of Open Offer: http://www.lse.co.uk/share-regulatory-news.asp?shareprice=FDI&ArticleCode=cqyztqwf&ArticleHeadline=Result_of_Open_Offer

Keep your gussets ventilated, it's one thousand shares. It was always going to be volatile with such poor liquidity. Meanwhile, NASDAQ awaits and NBI has stabilised.

that's right, but I know that there is interest in both EPO and in the technology, quite apart from our other candidates. It seems to me that, once Oz has reported trial results of EPO in H2, we may begin to see speculation on a deal appearing in the share price. The rest of the cautionary stuff I see as standard caveats of the type seen in all Annual Results.

I understand from previous public-domain interviews with Mr Maguire that there has already been some considerable interest shown in licensing PSA-EPO from XBIO. I'm no expert but I think it's all a question of timing; in other words XBIO proving the worth of the formulation up to a certain point in trials, beyond which, if the latter are positive and a deal agreed for both licence and royalties, the interested party becomes responsible for bringing the product to market. That is my understanding anyway.

While on the surface I agree that looks scary, I assume that these kind of statements and disclosures are standard fare in reporting annual results in the US. Otherwise, it's difficult to understand how XBIO could have signed, a mere two months ago, a revised agreement with Baxter that commits the parties to a partnership extending into the distant future.

A certain degree of banter and levity has crept onto this thread recently, masking the serious business at hand. The usual suspects are gathered and one knows who the ringleader is. Make no mistake, my three-wheeled friend, one has one's glass, unmonocled eye on you. A wellwisher.

No, it's very simple: if you hold 10 shares now, you will have one new share. If the SP when that happens is £0.035, you will have £0.35 per share of new shares. In effect it has no effect on your worth. The only thing you should guard against is that, when the time comes you have whole number multiples of 10 shares, though at these prices that scarcely matters, you would only stand to lose at most about 30p.

it seems we are condemned for the time being to wander lost in the corridors of Valhalla; there is almost no liquidity to XBIO now, so we must hope that our Odin provides for us an early ascent to NASDAQ, a fund-raising of the kind that will release shares to the free float, and some concomitant good news, perhaps in the form of an OncoFest.

Xenetic Biosciences Announces Positive Phase 1 Clinical Data for PulmoXen(TM) for Treatment of Cystic Fibrosis http://www.otcmarkets.com/stock/XBIO/news

there is no cause for concern. The Snooty Grapevine, extensive and comprehensive as it is, informs me that, according to plans made clear in the recent Baxter deal, we are committed to enlistment on NASDAQ before October at the latest. I believe however that our elevation from the murky depths of OTC may occur sooner. Thus, if as you say, you have taken the sage advice of Snooty and plan to hold these nuggets at least to the medium term, then once listed on NASDAQ any old Tom, Dick or Harry UK broker will be able to handle the transaction for you after that time. For myself, I have concealed my certificates behind a false wall in the potting shed, since Her Ladyship has taken to nocturnal prowling.

$0.98 is nineteen pence old money after consolidation and exchange rate conversion so you've made eight pence per share.

that, whilst one has been in Eze partaking of a few invigorating Camparis and soda, quite the reverse has been happening here; here, the enervation engendered by the Singapore Swindler continues.

With today's RNS, another resoundingly successful venture from the people that brought you BK11 comes to a close.

It is interesting to note that, judging by yesterday's jiggery-pokery, the MMs on the other side of the Pond are just as prone to intimidation as their English counterparts. However, they have doubtless not reckoned with the experience and steel of the seasoned campaigners found here on the surrogate XBIO board. Trained and led as they have been by Snooty to overcome many and all vicissitudes, XBIOlogists will not be cowered! Forward, troops, to the Oasis of Plenty that is NASDAQ!

like old times.

With luck, Leeson will fall into a bunker and be buried by a sand landslide.

News needed to take us to the next level, Scott.

from Dutch's link below: March 21, 2014 The Drugs To Watch: New Report Identifies 20 Of The Most Promising For 2014 19. In December, Xenetic Biosciences and Russian company Pharmasynthez initiated a phase I trial of their cystic fibrosis treatment, PulmoXen, comprising a polysialylated formulation of recombinant human DNase I to help reduce the viscosity of infected lung secretions.

Word on the street in Cleethorpes is that a certain three-wheeler enthusiast is planning new spokes on his Robin if XBIO lists on NASDAQ.

However, if you really must jeopardise both your own and the futures of your helpless womenfolk by selling prematurely, I am told that Stocktrade will negotiate on your behalf - at a price.